Search

John M. Hoffmann

Examiner (ID: 5190, Phone: (571)272-1191 , Office: P/1741 )

Most Active Art Unit
1731
Art Unit(s)
1712, 1731, 1741, 1791, 1304, 1303
Total Applications
1565
Issued Applications
722
Pending Applications
142
Abandoned Applications
703

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17443816 [patent_doc_number] => 20220064321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTI-CD20 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/531011 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531011 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/531011
Anti-CD20 antibody Nov 18, 2021 Issued
Array ( [id] => 17687770 [patent_doc_number] => 20220195062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => DOSING REGIMEN OF COMBINATION OF ANTICD20 AND ANTI-BLYS ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/519063 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519063 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/519063
Dosing regimen of combination of ANTICD20 and anti-BlyS antibodies Nov 3, 2021 Issued
Array ( [id] => 17546727 [patent_doc_number] => 20220118068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Modulation of Proprotein Convertase Subtilisin/Kexin 9 Expression (PCSK9) with HSP 27 and/or HSP25 [patent_app_type] => utility [patent_app_number] => 17/515001 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515001 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/515001
Modulation of proprotein convertase subtilisin/kexin 9 expression (PCSK9) with HSP 27 and/or HSP25 Oct 28, 2021 Issued
Array ( [id] => 17595396 [patent_doc_number] => 20220144969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => METHODS FOR REDUCING CARDIOVASCULAR RISK [patent_app_type] => utility [patent_app_number] => 17/504921 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504921 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/504921
METHODS FOR REDUCING CARDIOVASCULAR RISK Oct 18, 2021 Abandoned
Array ( [id] => 17642011 [patent_doc_number] => 20220169749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK [patent_app_type] => utility [patent_app_number] => 17/500214 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21059 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500214 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/500214
PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK Oct 12, 2021 Pending
Array ( [id] => 17473984 [patent_doc_number] => 20220081488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB [patent_app_type] => utility [patent_app_number] => 17/495559 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495559 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/495559
REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB Oct 5, 2021 Abandoned
Array ( [id] => 17368331 [patent_doc_number] => 20220023383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS [patent_app_type] => utility [patent_app_number] => 17/493896 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493896 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/493896
Pharmaceutical compositions and methods targeting Wnt pathway proteins Oct 4, 2021 Issued
Array ( [id] => 17672716 [patent_doc_number] => 20220185883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 [patent_app_type] => utility [patent_app_number] => 17/484794 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484794 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/484794
METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 Sep 23, 2021 Abandoned
Array ( [id] => 18739619 [patent_doc_number] => 20230348578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/021912 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021912 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/021912
CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF Sep 1, 2021 Pending
Array ( [id] => 18964213 [patent_doc_number] => 11897964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Anti-PSGL-1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/460883 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 21264 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460883 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/460883
Anti-PSGL-1 antibodies and uses thereof Aug 29, 2021 Issued
Array ( [id] => 19265390 [patent_doc_number] => 20240209089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => CD8 BINDING POLYPEPTIDE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/017236 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017236 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/017236
CD8 BINDING POLYPEPTIDE AND USE THEREOF Jul 19, 2021 Pending
Array ( [id] => 20336550 [patent_doc_number] => 20250340670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO PTK7 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/016100 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016100 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/016100
Antibody specifically binding to PTK7 and use thereof Jul 15, 2021 Issued
Array ( [id] => 18157953 [patent_doc_number] => 20230024543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => METHODS OF TREATING ANAEMIA [patent_app_type] => utility [patent_app_number] => 17/370446 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 220629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17370446 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/370446
METHODS OF TREATING ANAEMIA Jul 7, 2021 Abandoned
Array ( [id] => 18656079 [patent_doc_number] => 20230301950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => METHOD FOR SELECTING CANCER PATIENTS FOR WHOM COMBINATION THERAPY WITH RETINOID AND CANCER THERAPEUTIC AGENT IS EFFECTIVE, AND COMBINATION MEDICAMENT WITH RETINOID AND CANCER THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 18/010686 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010686 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/010686
Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent Jun 27, 2021 Issued
Array ( [id] => 18610907 [patent_doc_number] => 20230277637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => METHOD FOR THE TREATMENT OF A VIRAL INFECTION WITH HUMAN ALPHA-1 ANTITRYPSIN [patent_app_type] => utility [patent_app_number] => 17/999362 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999362 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/999362
METHOD FOR THE TREATMENT OF A VIRAL INFECTION WITH HUMAN ALPHA-1 ANTITRYPSIN May 25, 2021 Pending
Array ( [id] => 18931099 [patent_doc_number] => 11883493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders [patent_app_type] => utility [patent_app_number] => 17/241628 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 93 [patent_figures_cnt] => 98 [patent_no_of_words] => 105545 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241628 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/241628
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders Apr 26, 2021 Issued
Array ( [id] => 19738352 [patent_doc_number] => 12215170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-TMPRSS6 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/916008 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 93 [patent_no_of_words] => 17829 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916008 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/916008
Anti-TMPRSS6 antibodies and uses thereof Apr 4, 2021 Issued
Array ( [id] => 18420213 [patent_doc_number] => 20230174674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME [patent_app_type] => utility [patent_app_number] => 17/916621 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916621 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/916621
PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME Apr 1, 2021 Pending
Array ( [id] => 17214521 [patent_doc_number] => 20210347858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/221515 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221515 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/221515
ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS Apr 1, 2021 Abandoned
Array ( [id] => 17185261 [patent_doc_number] => 20210332146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/211619 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211619 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/211619
Anti-CD20 glycoantibodies and uses thereof Mar 23, 2021 Issued
Menu